Alex Sirois

Alex Sirois

InvestorPlace Contributor

Alex is a freelance contributor to InvestorPlace who provides investment insight that is conversational, actionable, and educational. While he writes about all stock classes, his personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks.

Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing. His number one goal in writing for InvestorPlace is to bring value to the reader.

You can follow Alex on LinkedIn.

Recent Articles

Lemonade Remains a Cautionary Tale of Tech Updating Old Industry

By Alex Sirois, InvestorPlace Contributor

Lemonade promised more than it could deliver and profitability issues remain more than a year after its IPO. LMND stock has gone sour.

Rocket Lab is a Compelling Space SPAC with NASA Approval

By Alex Sirois, InvestorPlace Contributor

RKLB stock is truly worth a look and has big growth potential with recent SPAC funding, solid fundamentals, and big name contracts.

7 Agricultural Stocks to Buy as Cash-Rich Farmers Open Their Wallets

By Alex Sirois, InvestorPlace Contributor

Investors seeking agricultural stocks to buy should look to the booming heartland of America, where farmers are spending hand over fist.

Rebound Promise of Carnival Stock Leaves Many Once Bitten Twice Shy

By Alex Sirois, InvestorPlace Contributor

Investors should avoid CCL stock as very little has changed and Carnival hasn't fulfilled its promise since the pandemic began.

Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility

By Alex Sirois, InvestorPlace Contributor

SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, but likely smart

Load More